Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
February 13 2024 - 2:47PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13G/A
Under
the Securities Exchange Act of 1934
(Amendment
No. 1)*
|
Cyclacel
Pharmaceuticals, Inc. |
(Name
of Issuer) |
|
Common
Stock, par value $0.001 per share |
(Title
of Class of Securities) |
|
|
23254L801 |
(CUSIP
Number) |
|
December
31, 2023 |
(Date
of Event Which Requires Filing of this Statement) |
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
|
☐ |
Rule
13d-1(b) |
|
☒ |
Rule
13d-1(c) |
|
☐ |
Rule
13d-1(d) |
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided
in a prior cover page.
The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
Page
2 of 9
1 |
NAME
OF REPORTING PERSONS
Altium Capital Management, LP
I.R.S.
IDENTIFICATION NO. OF ABOVE PERSONS
(ENTITIES ONLY) EIN: 82-2066653 |
|
2 |
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a)
☐
(b)
☐ |
3 |
SEC
USE ONLY |
|
4 |
CITIZENSHIP
OR PLACE OF ORGANIZATION
Delaware,
United States of America |
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH: |
5 |
SOLE
VOTING
0 |
|
6 |
SHARED
VOTING POWER
37,982
shares of Common Stock
194,100
shares of Common Stock issuable upon exercise of 2023 Warrants(1)
109,850
shares of Common Stock issuable upon exercise of Pre-Funded Warrants(1)
30,000
shares of Common Stock issuable upon exercise of Warrants(1) |
|
7 |
SOLE
DISPOSITIVE POWER
0 |
|
8 |
SHARED
DISPOSITIVE POWER
37,982
shares of Common Stock
194,100
shares of Common Stock issuable upon exercise of 2023 Warrants(1)
109,850
shares of Common Stock issuable upon exercise of Pre-Funded Warrants(1)
30,000
shares of Common Stock issuable upon exercise of Warrants(1) |
|
9 |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
37,982
shares of Common Stock
194,100
shares of Common Stock issuable upon exercise of 2023 Warrants(1)
109,850
shares of Common Stock issuable upon exercise of Pre-Funded Warrants(1)
30,000
shares of Common Stock issuable upon exercise of Warrants(1) |
|
10 |
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES |
☐ |
11 |
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.99%(1)(2) |
|
12 |
TYPE
OF REPORTING PERSON
IA,
PN |
|
|
|
|
|
|
| (1) | As
more fully described in Item 4, 2023 Warrants, the Prefunded Warrants, and Warrants (collectively the “Reported Warrants”)
are each subject to a 4.99% blocker (the “Warrant Blockers”). The percentage set forth in Row 11 for each Reporting
Person gives effect to the Warrant Blockers. Consequently, as of the date of the event which requires the filing of this statement,
the Reporting Persons were not able exercise the Reported Warrants to the extent that in the aggregate the Fund would receive
shares of more than 4.99% of Common Stock of the Issuer. |
| (2) | Based
on 1,019,310 shares of Common Stock outstanding as reported in the Issuer’s Form 424(b)(5) dated December 21, 2023, and
filed with the Securities and Exchange Commission on December 26, 2023. |
Page
3 of 9
1 |
NAME
OF REPORTING PERSONS
Altium Growth Fund, LP
I.R.S.
IDENTIFICATION NO. OF ABOVE PERSONS
(ENTITIES ONLY) EIN: 82-2105101 |
|
2 |
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a)
☐
(b)
☐ |
3 |
SEC
USE ONLY |
|
4 |
CITIZENSHIP
OR PLACE OF ORGANIZATION
Delaware,
United States of America |
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH: |
5 |
SOLE
VOTING
0 |
|
6 |
SHARED
VOTING POWER
37,982
shares of Common Stock
194,100
shares of Common Stock issuable upon exercise of 2023 Warrants(1)
109,850
shares of Common Stock issuable upon exercise of Pre-Funded Warrants(1)
30,000
shares of Common Stock issuable upon exercise of Warrants(1) |
|
7 |
SOLE
DISPOSITIVE POWER
0 |
|
8 |
SHARED
DISPOSITIVE POWER
37,982
shares of Common Stock
194,100
shares of Common Stock issuable upon exercise of 2023 Warrants(1)
109,850
shares of Common Stock issuable upon exercise of Pre-Funded Warrants(1)
30,000
shares of Common Stock issuable upon exercise of Warrants(1) |
|
9 |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
37,982
shares of Common Stock
194,100
shares of Common Stock issuable upon exercise of 2023 Warrants(1)
109,850
shares of Common Stock issuable upon exercise of Pre-Funded Warrants(1)
30,000
shares of Common Stock issuable upon exercise of Warrants(1) |
|
10 |
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES |
☐ |
11 |
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.99%(1)(2) |
|
12 |
TYPE
OF REPORTING PERSON
PN |
|
|
|
|
|
|
| (1) | As
more fully described in Item 4, 2023 Warrants, the Prefunded Warrants, and Warrants (collectively
the “Reported Warrants”) are each subject to a 4.99% blocker (the “Warrant
Blockers”). The percentage set forth in Row 11 for each Reporting Person gives
effect to the Warrant Blockers. Consequently, as of the date of the event which requires
the filing of this statement, the Reporting Persons were not able exercise the Reported
Warrants to the extent that in the aggregate the Fund would receive shares of more than
4.99% of Common Stock of the Issuer. |
| (2) | Based
on 1,019,310 shares of Common Stock outstanding as reported in the Issuer’s Form
424(b)(5) dated December 21, 2023, and filed with the Securities and Exchange Commission
on December 26, 2023. |
Page
4 of 9
|
|
|
|
|
1 |
NAME OF REPORTING PERSONS
Altium Growth GP, LLC
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
(ENTITIES ONLY) EIN: 82-2086430 |
|
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) ☐
(b) ☐ |
3 |
SEC USE ONLY |
|
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware, United States of America |
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH: |
5 |
SOLE VOTING
0 |
|
6 |
SHARED VOTING POWER
37,982 shares of Common Stock
194,100 shares of Common Stock issuable upon exercise
of 2023 Warrants(1)
109,850 shares of Common Stock issuable upon exercise
of Pre-Funded Warrants(1)
30,000 shares of Common Stock issuable upon exercise
of Warrants(1) |
|
7 |
SOLE DISPOSITIVE POWER
0 |
|
8 |
SHARED DISPOSITIVE POWER
37,982 shares of Common Stock
194,100 shares of Common Stock issuable upon exercise
of 2023 Warrants(1)
109,850 shares of Common Stock issuable upon exercise
of Pre-Funded Warrants(1)
30,000 shares of Common Stock issuable upon exercise
of Warrants(1) |
|
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
37,982 shares of Common Stock
194,100 shares of Common Stock issuable upon exercise
of 2023 Warrants(1)
109,850 shares of Common Stock issuable upon exercise
of Pre-Funded Warrants(1)
30,000 shares of Common Stock issuable upon exercise
of Warrants(1) |
|
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES |
☐ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW
9
4.99%(1)(2) |
|
12 |
TYPE OF REPORTING PERSON
OO |
|
| (1) | As
more fully described in Item 4, 2023 Warrants, the Prefunded Warrants, and Warrants (collectively the “Reported Warrants”)
are each subject to a 4.99% blocker (the “Warrant Blockers”). The percentage set forth in Row 11 for each Reporting
Person gives effect to the Warrant Blockers. Consequently, as of the date of the event which requires the filing of this statement,
the Reporting Persons were not able exercise the Reported Warrants to the extent that in the aggregate the Fund would receive
shares of more than 4.99% of Common Stock of the Issuer. |
| (2) | Based
on 1,019,310 shares of Common Stock outstanding as reported in the Issuer’s Form 424(b)(5) dated December 21, 2023, and
filed with the Securities and Exchange Commission on December 26, 2023. |
Page
5 of 9
Item
1(a). |
|
Name
of Issuer: Cyclacel
Pharmaceuticals, Inc. (the “Issuer”) |
|
|
|
|
|
|
Item
1(b). |
|
Address
of Issuer’s Principal Executive Offices: 200 Connell Drive, Suite 1500
Berkeley
Heights, NJ 07922 |
|
|
|
|
|
|
Item
2(a). |
|
Name
of Person Filing:
This
statement is jointly filed by and on behalf of each of Altium Growth Fund, LP (the “Fund”), Altium Capital
Management, LLC, and Altium Growth GP, LLC. The Fund is the record and direct beneficial owner of the securities covered
by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities,
owned by the Fund. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities,
owned by the Fund.
Each
reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission
that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner
of any securities covered by this statement.
Each
of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer
for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing
of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section
13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other
person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing
of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of
any group with respect to the Issuer or any securities of the Issuer.
|
|
|
|
|
|
|
|
|
|
Item
2(b). |
|
Address
of Principal Business Office or, if None, Residence: |
|
|
The
address of the principal business office of each of the reporting persons is
152 West 57th Street, FL 20, New York, NY 10019 |
|
|
|
|
|
|
Item
2(c). |
|
Citizenship: |
|
|
See
Item 4 on the cover page(s) hereto. |
|
|
|
|
|
|
Item
2(d). |
|
Title
of Class of Securities: |
|
|
Common
Stock, par value $0.001 per share (“Common Stock”) |
|
|
|
|
|
|
Item
2(e). |
|
CUSIP
Number: 23254L801 |
|
|
|
|
|
|
Item
3. |
If
This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a: |
|
|
|
(a) |
☐ |
Broker
or dealer registered under Section 15 of the Act (15 U.S.C. 78o). |
|
|
|
|
|
(b) |
☐ |
Bank
as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). |
Page
6 of 9
|
|
|
|
|
(c) |
☐ |
Insurance
company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). |
|
|
|
|
|
(d) |
☐ |
Investment
company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). |
|
|
|
|
|
(e) |
☐ |
An
investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); |
|
|
|
|
|
(f) |
☐ |
An
employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); |
|
|
|
|
|
(g) |
☐ |
A
parent holding company or control person in accordance with §240.13d-1(b)(ii)(G); |
|
|
|
|
|
(h) |
☐ |
A
savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
|
|
|
|
|
(i) |
☐ |
A
church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company
Act (15 U.S.C. 80a-3); |
|
|
|
|
|
(j) |
☐ |
Group,
in accordance with §240.13d-1(b)(1)(ii)(J). |
|
|
|
|
Item
4. |
Ownership. |
|
Provide
the following information regarding the aggregate number and percentage of the class
of securities of the issuer identified in Item 1.
The
information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is
set forth in Rows 5 – 11 of the cover page for each Reporting Person listed above and is incorporated by reference
for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based
on 1,019,310 shares of Common Stock outstanding as reported in the Issuer’s Form 424(b)(5) dated December 21, 2023,
and filed with the Securities and Exchange Commission on December 26, 2023.
Pursuant
to the terms of the securities purchase agreement entered into between the Fund and the Issuer, the Fund purchased Common
Stock, 2023 Warrants, Prefunded Warrants, and Warrants (collectively the “Reported Warrants”). The Reporting
Persons cannot exercise the Reported Warrants to the extent the Reporting Persons would beneficially own, after any such
exercise, more than 4.99% of the outstanding shares of Common Stock (the “Warrant Blockers”).
The
percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Warrant Blockers. Consequently,
as of the date of the event which requires the filing of this statement, the Reporting Persons were not able exercise
the Reported Warrants to the extent that in the aggregate the Fund would receive shares of more than 4.99% of Common Stock
of the Issuer.
|
|
|
|
|
Page
7 of 9
Item
5. |
Ownership
of Five Percent or Less of a Class. |
|
|
|
If
this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner
of more than five percent of the class of securities, check the following ☒ |
|
|
Item 6. |
Ownership of
More than Five Percent on Behalf of Another Person. |
|
Not applicable |
|
|
|
|
Item 7. |
Identification
and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control
Person. |
|
Not applicable |
|
|
|
|
Item 8. |
Identification
and Classification of Members of the Group. |
|
Not applicable |
|
|
|
|
Item 9. |
Notice of Dissolution
of Group. |
|
Not applicable |
|
|
Item 10. |
Certification. |
By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than
activities solely in connection with a nomination under § 240.14a-11.
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
|
Dated: |
February 13, 2024 |
|
|
|
|
Altium Capital Management, LP |
|
|
|
|
By: |
/s/ Jacob Gottlieb |
|
Name: |
Jacob Gottlieb |
|
Title: |
CEO |
|
Altium Growth Fund, LP |
|
|
|
By: |
Altium Growth GP, LLC |
|
Its: |
General Partner |
|
|
|
Signature: |
/s/
Jacob Gottlieb |
|
Name: |
Jacob Gottlieb |
|
Title: |
Managing Member
of Altium Growth GP, LLC |
|
|
|
|
Altium
Growth GP, LLC |
|
|
|
By: |
/s/
Jacob Gottlieb |
|
Name: |
Jacob Gottlieb |
|
Title: |
Managing Member |
Page
8 of 9
EXHIBIT
INDEX
Page 9 of 9
Altium Capital Management, LP SC 13G/A
EXHIBIT
1
JOINT
ACQUISITION STATEMENT
PURSUANT
TO SECTION 240.13d-1(k)
The
undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and
that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the
necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible
for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained
therein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons,
except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.
|
Dated: |
February 13, 2024 |
|
|
|
|
Altium Capital Management, LP |
|
|
|
|
By: |
/s/ Jacob Gottlieb |
|
Name: |
Jacob Gottlieb |
|
Title: |
CEO |
|
Altium Growth Fund, LP |
|
|
|
|
By: |
Altium Growth GP, LLC |
|
Its: |
General Partner |
|
Signature: |
/s/
Jacob Gottlieb |
|
Name: |
Jacob Gottlieb |
|
Title: |
Managing Member
of Altium Growth GP, LLC |
|
|
|
|
Altium
Growth GP, LLC |
|
|
|
By: |
/s/
Jacob Gottlieb |
|
Name: |
Jacob Gottlieb |
|
Title: |
Managing Member |
|
|
|
Cyclacel Pharmaceuticals (NASDAQ:CYCCP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCCP)
Historical Stock Chart
From Sep 2023 to Sep 2024